Intellia Therapeutics Inc (NASDAQ:NTLA) shares rose 6.4% on Thursday . The company traded as high as $26.06 and last traded at $24.02. Approximately 326,619 shares changed hands during trading, a decline of 67% from the average daily volume of 975,602 shares. The stock had previously closed at $25.65.

NTLA has been the topic of a number of research reports. Leerink Swann upped their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Credit Suisse Group upped their price target on Intellia Therapeutics from $24.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Barclays reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Finally, ValuEngine downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. Intellia Therapeutics has a consensus rating of “Hold” and an average price target of $30.17.

The firm has a market cap of $1,020.00 and a P/E ratio of -15.51.

In other news, CEO Nessan Bermingham sold 111,500 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the completion of the sale, the chief executive officer now directly owns 696,000 shares of the company’s stock, valued at $14,156,640. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,521,928 shares of company stock valued at $51,883,434. Company insiders own 12.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of NTLA. GMT Capital Corp purchased a new stake in shares of Intellia Therapeutics during the third quarter valued at approximately $8,214,000. Capital Advisors Inc. OK purchased a new stake in shares of Intellia Therapeutics during the fourth quarter valued at approximately $1,946,000. Ark Investment Management LLC increased its position in shares of Intellia Therapeutics by 118.9% during the second quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after acquiring an additional 94,960 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 10.2% during the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after acquiring an additional 92,580 shares during the last quarter. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $1,132,000. 48.12% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/intellia-therapeutics-ntla-stock-price-up-6-4/1853311.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.